Enzon Pharmaceuticals, Inc.

Published Date: 10/06/2011
Category: Therapies & Markets

Research Report Decription

Enzon Pharmaceuticals, Inc. - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Features:

• Detailed information on Enzon Pharmaceuticals, Inc. required for business and competitor intelligence needs
• A study of the major internal and external factors affecting Enzon Pharmaceuticals, Inc. in the form of a SWOT analysis
• An in-depth view of the business model of Enzon Pharmaceuticals, Inc. including a breakdown and examination of key business segments
• Intelligence on Enzon Pharmaceuticals, Inc.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
• News about Enzon Pharmaceuticals, Inc., such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends

Key Questions Answered:

• Gain understanding of the Enzon Pharmaceuticals, Inc. and the factors that influence its strategies 
• Track strategic initiatives of the company and latest corporate news and actions 
• Assess Enzon Pharmaceuticals, Inc. as a prospective partners, vendor or supplier
• Support sales activities by understanding your customers' businesses better
• Stay up to date on Enzon Pharmaceuticals, Inc.’s business structure, strategy and prospects

Companies Mentioned:

Enzon Pharmaceuticals, Inc.

Paper Highlights:

Enzon Pharmaceuticals (Enzon) is a biopharmaceutical company engaged in the development of innovative medicines for patients with cancer. The company primarily operates in the US and Europe. It is headquartered in Bridgewater, New Jersey and employed 317 people as of December 31, 2009. The company recorded revenues of $184.7 million during the financial year (FY) ended December 2009, a decrease of 6.2% over FY2008. The operating profit of the company was $0.6 million during FY2009, as compared with an operating profit of $3.1 million in FY2008. The net profit was $0.7 million in FY2009, as compared to a net loss of $2.7 million in FY2008.